FINAL DOSE FORM MANUFACTURING PROCESS VARIATIONS
Executive Summary
FINAL DOSE FORM MANUFACTURING PROCESS VARIATIONS between different ANDA applicants using the same bulk drug supplier justify continued bioequivalence testing for each separate ANDA, FDA Bioequivalence Division Director Shrikant Dighe, PhD, noted in a July 15 letter to Mallinckrodt. Responding to Mallinckrodt's proposal to allow bioequivalence testing on bulk drugs to apply to subsequent ANDA's, without doing individual testing, Dighe wrote that "your proposal would involve reliance on your bioequivalence testing by not just one applicant but by many different ANDA applicants. And, under your proposal not only would a different formulation be possible from each applicant . . . but it is highly unlikely that the tablets you make would be made under the same conditions and on the identical equipment as those made by each of your customers." The FDA official continued: "It is also likely that each manufacturer might have to modify the formulation of the product to accommodate the manufacturing procedures, equipment and environment at their respective facilities. Thus in time, we could expect 'drift' from a once common formulation to potentially different formulations for each manufacturer." Mallinckrodt suggested the ANDA testing changes in an April 21 letter to FDA, in which it made reference to a drug master file for bioequivalence an dissolution studies. "Each specific drug product," Dighe replied, "must stand on its own, that is, each ANDA must contain information to show that the product is bioequivalent to the listed drug product." Dighe stressed the difference between a final "drug product" and a bulk "drug substance." "Assurance about quality or bioavailability, for example, made about the latter cannot automatically or consistently be extrapolated to the former," he said. Manufacturing variations, such as in the tableting process, required "certain testing on each separate and specific drug product," Dighe noted. "For example, even in those cases where the same ANDA holder (or applicant) changes its manufacturing site and seeks to perform comparative dissolution studies in lieu of in vivo studies to demonstrate bioequivalence for the products made at different sites, an in vivo test on the finished drug product may be required unless the formulation is virtually identical at both sites and the manufacturing process (including manufacturing procedure and equipment, among others) is identical."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth